Management von Diabetespatienten in der COVID-19-Pandemie

ZUSAMMENFASSUNG

Über 10 % der deutschen Bevölkerung leiden an metabolischen Krankheiten wie Diabetes, Adipositas, oder nicht alkoholischer Steatohepatitis. Betroffene sind während der COVID-19-Pandemie einem besonderen Risiko ausgesetzt, gibt es doch zahlreiche Hinweise auf eine bidirektionale Beziehung zwischen diesen Krankheiten und COVID-19. Einerseits besteht ein deutlich erhöhtes Risiko für das Auftreten schwerer Krankheitsverläufe bis hin zum Tod, andererseits kann eine COVID-19-Infektion bereits bestehende metabolische Störungen verschlimmern oder neu hervorrufen. Wir werden hier die aktuelle Datenlage bezüglich der pathophysiologischen Mechanismen, die zu dieser bidirektionalen Beziehung führen, zusammenfassen und Empfehlungen für den Umgang mit solchen Patienten während und nach einer Infektion aussprechen.

Publication History

Article published online:
24 February 2022

• Literatur

• 1 Mahamat-Saleh Y, Fiolet T, Rebeaud ME. et al Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies. BMJ Open 2021; 11: e052777
• 2 Heidarpour M, Abhari AP, Sadeghpour N. et al Prediabetes and COVID-19 severity, an underestimated risk factor: A systematic review and meta-analysis. Diabetes Metab Syndr 2021; 15: 102307
• 3 Kumar A, Arora A, Sharma P. et al Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr 2020; 14: 535-545
• 4 Sahni S, Gupta G, Sarda R. et al Impact of metabolic and cardiovascular disease on COVID-19 mortality: A systematic review and meta-analysis. Diabetes Metab Syndr 2021; 5: 102308
• 5 Kim NH, Kim KJ, Choi J, Kim SG.. Metabolically unhealthy individuals, either with obesity or not, have a higher risk of critical coronavirus disease 2019 outcomes than metabolically healthy individuals without obesity. Metabolism. 2021: 154894
• 6 Xiao F, Zhou YC, Zhang MB. et al Hyperglycemia and blood glucose deterioration are risk factors for severe COVID-19 with diabetes: A two-center cohort study. J Med Virol. 2021
• 7 Eskenazi B, Rauch S, Iurlaro E. et al Diabetes mellitus, maternal adiposity, and insulin-dependent gestational diabetes are associated with Covid-19 in pregnancy: The INTERCOVID Study. Am J Obstet Gynecol. 2021
• 8 Endo K, Miki T, Itoh T. et al Impact of the COVID-19 Pandemic on Glycemic Control and Blood Pressure Control in Patients with Diabetes in Japan. Intern Med 2022; 61: 37-48
• 9 Wang W, Chai Z, Cooper ME. et al High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 Outcome. Front Endocrinol (Lausanne). 2021; 12: 791476
• 10 Kim JS, Lee JY, Yang JW. et al Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics 2021; 11: 316-329
• 11 Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature 2017; 542: 177-185
• 12 Berrou J, Fougeray S, Venot M. et al Natural killer cell function, an important target for infection and tumor protection, is impaired in type 2 diabetes. PLoS One 2013; 8: e62418
• 13 Xia C, Rao X, Zhong J. Role of T Lymphocytes in Type 2 Diabetes and Diabetes-Associated Inflammation. J Diabetes Res 2017; 2017: 6494795
• 14 Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev 2021; 37: e3377
• 15 Le Goff B, Berthelot JM, Maugars Y, Romas E. Alternative use of bisphosphonate therapy for rheumatic disease. Curr Pharm Des 2010; 16: 3045-3052
• 16 Zheng H, Wu J, Jin Z, Yan LJ. Potential Biochemical Mechanisms of Lung Injury in Diabetes. Aging Dis 2017; 8: 7-16
• 17 Upadhyay J, Farr O, Perakakis N. et al Obesity as a Disease. Med Clin North Am 2018; 102: 13-33
• 18 Kaul K, Tarr JM, Ahmad SI. et al Introduction to diabetes mellitus. Adv Exp Med Biol 2012; 771: 1-11
• 19 Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 2021; 17: 11-30
• 20 Steenblock C, Schwarz PEH, Ludwig B. et al COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol 2021; 9: 786-798
• 21 Thomas MC, Brownlee M. et al Diabetic kidney disease. Nat Rev Dis Primers 2015; 1: 15018
• 22 Menon R, Otto EA, Sealfon R. et al SARS-CoV-2 receptor networks in diabetic and COVID-19-associated kidney disease. Kidney Int 2020; 98: 1502-1518
• 23 Diao B, Wang C, Wang R. et al Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun 2021; 12: 2506
• 24 Cheng Y, Luo R, Wang K. et al Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97: 829-838
• 25 Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol 2020; 52: 1193-1194
• 26 Portoles J, Marques M, Lopez-Sanchez P. et al Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak. Nephrol Dial Transplant 2020; 35: 1353-1361
• 27 Carriazo S, Kanbay M, Ortiz A. Kidney disease and electrolytes in COVID-19: more than meets the eye. Clin Kidney J 2020; 13: 274-280
• 28 Steenblock C, Richter S, Berger I. et al Viral infiltration of pancreatic islets in patients with COVID-19. Nat Commun 2021; 12: 3534
• 29 Maestre-Muniz MM, Arias A, Mata-Vazquez E. et al Long-Term Outcomes of Patients with Coronavirus Disease 2019 at One Year after Hospital Discharge. J Clin Med 2021; 10: 2945
• 30 Kumaran NK, Karmakar BK, Taylor OM. Coronavirus disease-19 (COVID-19) associated with acute necrotising pancreatitis (ANP). BMJ Case Rep 2020; 13: e237903
• 31 Ayoubkhani D, Khunti K, Nafilyan V. et al Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ 2021; 372: n693
• 32 Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021; 594: 259-264
• 33 Mohammad RA, Nguyen CT, Costello PG. et al Medication Changes and Diagnosis of New Chronic Illnesses in COVID-19 Intensive Care Unit Survivors. Ann Pharmacother. 2022: 1 0600280211063319
• 34 The OpenSAFELY Collaborative Tazare J, Tomlinson L, Hickman G. et al Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19: a descriptive cohort study within the OpenSAFELY platform. 2021
• 35 Barrett CE, Koyama AK, Alvarez P. et al Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years – United States, March 1, 2020–June 28, 2021. MMWR Morb Mortal Wkly Rep 2022; 71: 59-65
• 36 Unsworth R, Wallace S, Oliver NS. et al New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care 2020; 43: e170-e171
• 37 Vlad A, Serban V, Timar R. et al Increased Incidence of Type 1 Diabetes during the COVID-19 Pandemic in Romanian Children. Medicina (Kaunas) 2021; 57: 973
• 38 Kamrath C, Monkemoller K, Biester T. et al Ketoacidosis in Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the COVID-19 Pandemic in Germany. JAMA 2020; 324: 801-804
• 39 Delpeut J, Giani E, Louet D. et al Variable incidence of ketoacidosis in youth with type 1 diabetes onset during Covid-19 pandemic peaks in France. Diabetes Metab. 2022: 101322
• 40 Ammar A, Brach M, Trabelsi K. et al Effects of COVID-19 Home Confinement on Eating Behaviour and Physical Activity: Results of the ECLB-COVID19 International Online Survey. Nutrients 2020; 12: 1583
• 41 Rowlands AV, Henson JJ, Coull NA. et al The impact of COVID-19 restrictions on accelerometer-assessed physical activity and sleep in individuals with type 2 diabetes. Diabet Med 2021; 38: e14549
• 42 Ruissen MM, Regeer H, Landstra CP. et al Increased stress, weight gain and less exercise in relation to glycemic control in people with type 1 and type 2 diabetes during the COVID-19 pandemic. BMJ Open Diabetes Res Care 2021; 9: e002035
• 43 Almandoz JP, Xie L, Schellinger JN. et al Impact of COVID-19 stay-at-home orders on weight-related behaviours among patients with obesity. Clin Obes 2020; 10: e12386
• 44 Bennett G, Young E, Butler I, Coe S. The Impact of Lockdown During the COVID-19 Outbreak on Dietary Habits in Various Population Groups: A Scoping Review. Front Nutr 2021; 8: 626432
• 45 Martinez-Ferran M, de la Guia-Galipienso F, Sanchis-Gomar F, Pareja-Galeano H. Metabolic Impacts of Confinement during the COVID-19 Pandemic Due to Modified Diet and Physical Activity Habits. Nutrients 2020; 12: 1549
• 46 Haynes SC, Kompala T, Tancredi DJ. et al Factors Associated With Discontinuation of Subspecialty Diabetes Care During the COVID-19 Pandemic: A Multisite Retrospective Cohort Study. Diabetes Care 2022; 45: e34-e36
• 47 Kuehn BM. Younger Adults With Diabetes Miss Care, Disregard COVID-19 Precautions. JAMA 2022; 327: 116
• 48 Chudasama YV, Gillies CL, Zaccardi F. et al Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals. Diabetes Metab Syndr 2020; 14: 965-967
• 49 Purvis RS, Moore RA, Ayers BL. et al Diabetes Self-Care Behaviors and Barriers to Clinical Care During COVID-19 Pandemic for Marshallese Adults. Sci Diabetes Self Manag Care. 2020 26350106211065390
• 50 Ozdin S, Bayrak Ozdin S. Levels and predictors of anxiety, depression and health anxiety during COVID-19 pandemic in Turkish society: The importance of gender. Int J Soc Psychiatry 2020; 66: 504-511
• 51 Hossain MM, Tasnim S, Sultana A. et al Epidemiology of mental health problems in COVID-19: a review. F1000Res 2020; 9: 636
• 52 Lei L, Huang X, Zhang S. et al Comparison of Prevalence and Associated Factors of Anxiety and Depression Among People Affected by versus People Unaffected by Quarantine During the COVID-19 Epidemic in Southwestern China. Med Sci Monit 2020; 26: e924609
• 53 Cyranka K, Dudek D, Malecki MT. et al Psychological Crisis Intervention for COVID-19 Lockdown Stress in Patients With Type 1 Diabetes Mellitus: Survey Study and Qualitative Analysis. JMIR Ment Health 2021; 8: e28097
• 54 Durmus M, Ciftci N, Gercek A, Durmus Y.. The Effect of COVID -19 Crisis on Hopelessness, Loneliness and Spiritual Well-Being of Patients with Type 1 and Type 2 Diabetes in Turkey. J Relig Health. 2022
• 55 Group RC, Horby P, Lim WS. et al Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021; 384: 693-704
• 56 Group WHOREAfC-TW Sterne JAC, Murthy S, Diaz JV. et al Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA 2020; 324: 1330-1341
• 57 Perez A, Jansen-Chaparro S, Saigi I. et al Glucocorticoid-induced hyperglycemia. J Diabetes 2014; 6: 9-20
• 58 Santos A, Magro DO, Evangelista-Poderoso R, Saad MJA. Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. Diabetol Metab Syndr 2021; 13: 23
• 59 Kow CS, Hasan SS. Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: A meta-analysis. J Med Virol 2021; 93: 695-697
• 60 Scheen AJ. Metformin and COVID-19: From cellular mechanisms to reduced mortality. Diabetes Metab 2020; 46: 423-426
• 61 Cheng X, Liu YM, Li H. et al Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab 2020; 32: 537-47 e3
• 62 Ojeda-Fernandez L, Foresta A, Macaluso G. et al Metformin use is associated with a decrease in risk of hospitalization and mortality in COVID-19 diabetic patients: a population-based study in Lombardy. Diabetes Obes Metab. 2022
• 63 Khunti K, Knighton P, Zaccardi F. et al Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol 2021; 9: 293-303
• 64 Kosiborod MN, Esterline R, Furtado RHM. et al Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2021; 9: 586-594
• 65 Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?. J Diabetes Complications 2020; 34: 107723
• 66 Nohara H, Nakashima R, Kamei S. et al Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases. Biochem Biophys Res Commun 2020; 524: 332-339
• 67 Bouhanick B, Cracowski JL, Faillie JL. DPP-4 inhibitors and severe course of illness in patients with COVID-19. Therapie 2021; 76: 359-360
• 68 Noh Y, Oh IS, Jeong HE. et al Association Between DPP-4 Inhibitors and COVID-19-Related Outcomes Among Patients With Type 2 Diabetes. Diabetes Care 2021; 44: e64-e66
• 69 Rhee SY, Lee J, Nam H. et al Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19. Diabetes Metab J 2021; 45: 251-259
• 70 Pal R, Banerjee M, Mukherjee S. et al Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis. Ther Adv Endocrinol Metab. 2021 12. 2042018821996482
• 71 Solerte SB, D’Addio F, Trevisan R. et al Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes Care 2020; 43: 2999-3006
• 72 Dandona P, Ghanim H. Diabetes, Obesity, COVID-19, Insulin, and Other Antidiabetes Drugs. Diabetes Care 2021; 44: 1929-1933
• 73 Yu B, Li C, Sun Y, Wang DW. Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes. Cell Metab 2021; 33: 65-77 e2
• 74 Sourij C, Tripolt NJ, Aziz F. et al Humoral immune response to Covid-19 vaccination in diabetes: age-dependent but independent of type of diabetes and glycaemic control – the prospective COVAC-DM cohort study. Diabetes Obes Metab. 2022
• 75 Pal R, Bhadada SK, Misra A. COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges. Diabetes Metab Syndr 2021; 15: 505-508
• 76 McGovern AP, Thomas NJ, Vollmer SJ. et al The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation. Diabetologia 2021; 64: 1184-1186
• 77 Petrie JR, Boyle JG, Ali K. et al A post COVID-19 ‘Marshall Plan’ for type 2 diabetes. Diabet Med 2021; 38: e14439
• 78 Saiyed S, Joshi R, Khattab S, Dhillon S. The Rapid Implementation of an Innovative Virtual Diabetes Boot Camp Program: Case Study. JMIR Diabetes 2022; 7: e32369
• 79 Hamrouni M, Roberts MJ, Thackray A. et al Associations of obesity, physical activity level, inflammation and cardiometabolic health with COVID-19 mortality: a prospective analysis of the UK Biobank cohort. BMJ Open 2021; 11: e055003
• 80 Sallis R, Young DR, Tartof SY. et al Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients. Br J Sports Med 2021; 55: 1099-1105
• 81 Ruberti OM, Telles GD, Rodrigues B. Stress and Physical Inactivity: Two Explosive Ingredients for the Heart in COVID-19 Pandemic Times. Curr Cardiol Rev 2021; 17: 6-14
• 82 Raveendran AV, Misra A. Post COVID-19 Syndrome (“Long COVID”) and Diabetes: Challenges in Diagnosis and Management. Diabetes Metab Syndr 2021; 15: 102235
• 83 Sudre CH, Murray B, Varsavsky T. et al Attributes and predictors of long COVID. Nat Med 2021; 27: 626-631
• 84 Fernandez-de-Las-Penas C, Guijarro C, Torres-Macho J. et al Diabetes and the Risk of Long-term Post-COVID Symptoms. Diabetes 2021; 70: 2917-2921
• 85 Nalbandian A, Sehgal K, Gupta A. et al Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601-615
• 86 Montefusco L, Ben Nasr M, D’Addio F. et al Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab 2021; 3: 774-785
• 87 Unnikrishnan R, Misra A. Diabetes and COVID19: a bidirectional relationship. Nutr Diabetes 2021; 11: 21
• 88 Ramakrishnan RK, Kashour T, Hamid Q. et al Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19. Front Immunol 2021; 12: 686029
• 89 Yan Z, Yang M, Lai CL. Long COVID-19 Syndrome: A Comprehensive Review of Its Effect on Various Organ Systems and Recommendation on Rehabilitation Plans. Biomedicines 2021; 9: 966